In two cases, patients had a nonresectable node during the staging procedure which could be removed during the time of hysterectomy. Of the 16 final lymphadenectomies, 6 were positive and patients received a complementary boost of external irradiation on the involved removed nodes. Patients were followed every 4 months for the first year after treatment and then every 6 months until 5 years.

Thereafter, followup was done annually. Selumetinib order Primary end points were overall survival (OS) and disease-free survival (DFS), and LC calculated from the date of diagnosis by the Kaplan–Meier method (15). Events taken into account for OS were death of any cause, and for DFS relapses across, all sites were taken into account. LC was assessed at clinical examination and defined as absence of local recurrence (centropelvic, lateropelvic, or vaginal). Locoregional recurrences included local and pelvic nodes recurrences. Lomboaortic metastatic nodes were considered to be metastatic relapse. Median followup was calculated with the reverse Kaplan–Meier method. Univariate analysis, taking into account age (<40 years), FIGO stages (I and II vs. III and IV), nodal involvement (pathologically staged and radiologically involved nodes), histologic type, surgery, concomitant chemotherapy, and response to chemoradiation as predictive factors for OS and DFS, was performed using a log-rank test. For

LC, 3D planning BT and BT dose prescription (D100 HR CTV [EQD2 (10)] >15.8 Gy) were also analyzed. GS-7340 All variables significant at p < 0.05 were then included in a multivariate analysis with a Cox proportional hazards model using the stepwise ascending method of maximum likelihood after verification of data proportionality. The secondary end point was analysis of complications which were graded retrospectively using the Common Terminology Criteria of Adverse Events (CTCAE v3.0). Because of the difficulties in estimating low-grade toxicities in retrospective studies, we focused on

Grades 3 and 4 toxicity, although grades for all side effects were identified. “Delayed or late” toxicities were defined as all toxicities occurring after 6 months. Toxicities were compared using Pearson’s χ2 across treatment Arachidonate 15-lipoxygenase characteristics (surgical procedure, adjunction of chemotherapy, dose of EBRT, external irradiation technique, technical modalities of EBRT, and laparoscopic lymphadenectomy). Across DVH to bladder and rectum, toxicities were compared using a Mann–Whitney test. These characteristics are listed in Tables 1 and 2. Median patient age was 52 years (range, 26–82 years). The median pelvic dose was 45 Gy in 25 fractions, 5 days a week. Fifty-one patients underwent a complementary external irradiation boost (parametria and/or pelvic lymph nodes) with a median dose of 9 Gy (range, 8–10 Gy). The median dose for the PDR intracavitary boost was 16 Gy.